Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.
Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.
复制标题
肠道微生物群与抗糖尿病药物:2型糖尿病个性化治疗的前景
DOI:
10.3389/fcimb.2022.853771
复制
发表时间:
2022
影响因子:
5.7
通讯作者:
中科院分区:
文献类型:
--
作者:
Alterations in the composition and function of the gut microbiota have been reported in patients with type 2 diabetes mellitus (T2DM). Emerging studies show that prescribed antidiabetic drugs distort the gut microbiota signature associated with T2DM. Even more importantly, accumulated evidence provides support for the notion that gut microbiota, in turn, mediates the efficacy and safety of antidiabetic drugs. In this review, we highlight the current state-of-the-art knowledge on the crosstalk and interactions between gut microbiota and antidiabetic drugs, including metformin, α-glucosidase inhibitors, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, traditional Chinese medicines and other antidiabetic drugs, as well as address corresponding microbial-based therapeutics, aiming to provide novel preventative strategies and personalized therapeutic targets in T2DM.
登录
查看更多内容
影响因子:
4.6
作者:
Aoki R;Kamikado K;Suda W;Takii H;Mikami Y;Suganuma N;Hattori M;Koga Y
通讯作者:
Koga Y
影响因子:
29.4
作者:
Bouter, Kristien E.;van Raalte, Daniel H.;Nieuwdorp, Max
通讯作者:
Nieuwdorp, Max
影响因子:
5.8
作者:
Ejtahed, Hanieh-Sadat;Tito, Raul Y.;Larijani, Bagher
通讯作者:
Larijani, Bagher
影响因子:
8.2
作者:
Bryrup, Thomas;Thomsen, Caecilie W.;Nielsen, Trine
通讯作者:
Nielsen, Trine
DOI:
10.1124/jpet.118.248575
发表时间:
2018-06-01
影响因子:
3.5
作者:
Du, Fuyong;Hinke, Simon A.;Hornby, Pamela J.
通讯作者:
Hornby, Pamela J.